Pluri Inc. (PLUR)

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Research, Development, Clinical Trials and Manufacturing of Cell Therapeutics	1.34M	326.00K	287.00K	234.00K		23.00K
Research, Development, Clinical Trials and Manufacturing of Cell Therapeutics Growth	309.82%	13.59%	22.65%	-		-57.41%
Total	1.34M	326.00K	287.00K	234.00K		23.00K
Total Growth	309.82%	13.59%	22.65%	-		-57.41%

Revenue by Geography

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Israel	1.34M	326.00K	287.00K	234.00K		23.00K
Israel Growth	309.82%	13.59%	22.65%	-		-57.41%
Total	1.34M	326.00K	287.00K	234.00K		23.00K
Total Growth	309.82%	13.59%	22.65%	-		-57.41%

Data Source: S&P Global Market Intelligence Last updated: Feb 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 17, 2026

Data Sources Report a data error